Dr. Armstrong Discusses Hereditary Prostate Cancer

Andrew J. Armstrong, MD
Published: Wednesday, Nov 01, 2017



Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.

One of the most important findings of the past year was the identification of a form of hereditary prostate cancer, Armstrong says.

These mutations are called homologous repair enzymes, which create a very aggressive form of prostate cancer that effects 10% to 15% of men with metastatic prostate cancer.
 


Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.

One of the most important findings of the past year was the identification of a form of hereditary prostate cancer, Armstrong says.

These mutations are called homologous repair enzymes, which create a very aggressive form of prostate cancer that effects 10% to 15% of men with metastatic prostate cancer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x